A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates

[1]  A. Takada,et al.  Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. , 2019, Cell reports.

[2]  Erika L. Flannery,et al.  Plasmodium falciparum Liver Stage Infection and Transition to Stable Blood Stage Infection in Liver-Humanized and Blood-Humanized FRGN KO Mice Enables Testing of Blood Stage Inhibitory Antibodies (Reticulocyte-Binding Protein Homolog 5) In Vivo , 2018, Front. Immunol..

[3]  Juliana K. Wambua,et al.  Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. , 2017, JCI insight.

[4]  M. Higgins,et al.  Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’ , 2017, International journal for parasitology.

[5]  A. Lescano,et al.  A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection , 2017, npj Vaccines.

[6]  D. Conway,et al.  Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria , 2015, Immunity.

[7]  H. Ishida,et al.  Cytotoxic activities of CD8+ T cells collaborate with macrophages to protect against blood-stage murine malaria , 2015, eLife.

[8]  J. Rayner,et al.  Revealing the Sequence and Resulting Cellular Morphology of Receptor-Ligand Interactions during Plasmodium falciparum Invasion of Erythrocytes , 2015, PLoS pathogens.

[9]  Cécile Crosnier,et al.  A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys , 2015, Cell host & microbe.

[10]  Katherine E. Wright,et al.  Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies , 2014, Nature.

[11]  L. Marrama,et al.  Association of Antibody Responses to the Conserved Plasmodium falciparum Merozoite Surface Protein 5 with Protection against Clinical Malaria , 2014, PloS one.

[12]  Michel Theron,et al.  Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5 , 2014, The Journal of Immunology.

[13]  P. Siba,et al.  Opsonising Antibodies to P. falciparum Merozoites Associated with Immunity to Clinical Malaria , 2013, PloS one.

[14]  R. Cortese,et al.  ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  D. Kwiatkowski,et al.  Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens , 2012, PLoS pathogens.

[16]  P. Gilbert,et al.  Nomenclature for immune correlates of protection after vaccination. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. Gallagher-Jones,et al.  A benchmarked protein microarray-based platform for the identification of novel low-affinity extracellular protein interactions , 2012, Analytical biochemistry.

[18]  K. Marsh,et al.  Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody , 2011, Nature Communications.

[19]  Dominic P. Kwiatkowski,et al.  BASIGIN is a receptor essential for erythrocyte invasion by Plasmodium falciparum , 2011, Nature.

[20]  A. Thomas,et al.  Vaccination with Plasmodium knowlesi AMA1 Formulated in the Novel Adjuvant Co-Vaccine HT™ Protects against Blood-Stage Challenge in Rhesus Macaques , 2011, PloS one.

[21]  J. McCarthy,et al.  Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice. , 2010, The Journal of clinical investigation.

[22]  Cécile Crosnier,et al.  A rapid and scalable method for selecting recombinant mouse monoclonal antibodies , 2010, BMC Biology.

[23]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[24]  L. Marrama,et al.  Clinical Protection from Falciparum Malaria Correlates with Neutrophil Respiratory Bursts Induced by Merozoites Opsonized with Human Serum Antibodies , 2010, PloS one.

[25]  J. Barnwell,et al.  High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model , 2009, PloS one.

[26]  Peter D. Crompton,et al.  In Vitro Growth-Inhibitory Activity and Malaria Risk in a Cohort Study in Mali , 2009, Infection and Immunity.

[27]  M. Fay,et al.  Anti-Apical-Membrane-Antigen-1 Antibody Is More Effective than Anti-42-Kilodalton-Merozoite-Surface-Protein-1 Antibody in Inhibiting Plasmodium falciparum Growth, as Determined by the In Vitro Growth Inhibition Assay , 2009, Clinical and Vaccine Immunology.

[28]  A. Saul,et al.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. , 2008, Vaccine.

[29]  Hong Zhou,et al.  Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity , 2006, Infection and Immunity.

[30]  S. Stanworth,et al.  Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. , 2006, Blood.

[31]  D. Kaslow,et al.  Efficacy of Two Alternate Vaccines Based on Plasmodium falciparum Merozoite Surface Protein 1 in anAotus Challenge Trial , 2001, Infection and Immunity.

[32]  Kevin Marsh,et al.  Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria , 1998, Nature Medicine.

[33]  A. Tartar,et al.  Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes , 1994 .

[34]  Jaeger,et al.  Effects of cytokines, complement, and antibody on the neutrophil respiratory burst and phagocytic response to Plasmodium falciparum merozoites , 1992, Infection and immunity.

[35]  A. Sabchareon,et al.  Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. , 1991, The American journal of tropical medicine and hygiene.

[36]  A. Sabchareon,et al.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes , 1990, The Journal of experimental medicine.

[37]  L. Miller,et al.  Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Waldmann,et al.  Metabolic properties of IgG subclasses in man. , 1970, The Journal of clinical investigation.

[39]  L. Miller.  Distribution of mature trophozoites and schizonts of Plasmodium falciparum in the organs of Aotus trivirgatus, the night monkey. , 1969, The American journal of tropical medicine and hygiene.

[40]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[41]  G. Killeen,et al.  Limitation of using synthetic human odours to test mosquito repellents , 2009, Malaria Journal.

[42]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[43]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[44]  A. Tartar,et al.  Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. , 1994, Blood.